Johnson & Johnson has paused Phase 3 trials for its COVID-19 vaccine candidate, after one patient reported an “unexplained illness.” This comes after AstraZeneca paused its Phase 3 trials due to an adverse event, and Moderna slowed its trial because of enrollment difficulties.
Axios Re:Cap goes deeper with Tom Frieden, who led the Centers for Disease Control and Prevention between 2009 and 2017.
